Literature DB >> 8182636

Feasibility of utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia.

C Bakker1, M Rutten, E van Doorslaer, K Bennett, S van der Linden.   

Abstract

OBJECTIVE: To assess the feasibility of utility measurement in patients with ankylosing spondylitis (AS) or fibromyalgia (FMS). Patient derived utilities provide overall estimates of the impact of a disease on patient well being.
METHODS: The Maastricht Utility Measurement Questionnaire was applied cross sectionally to 57 patients with AS and 86 outpatients with FMS. By means of rating scale and standard gamble techniques, patients were asked to value their own health state.
RESULTS: All 143 patients completed the interview. Patients with AS valued their personal health state on the rating scale (0-100) considerably higher than patients with FMS (AS: 69 and FMS: 54). Standard gamble utility values (0-1), however, were about the same at a higher level (AS: 0.86 and FMS: 0.83). Four weeks test-retest reliability was examined in 15 patients with FMS. The intraclass correlation coefficient of the utility score for the patient's own health state was 0.56 for the rating scale and 0.66 for the standard gamble technique.
CONCLUSION: Feasibility of the Maastricht Utility Measurement Questionnaire was generally satisfactory in both patient groups. Utility values obtained by rating scale and standard gamble technique differed considerably. Our data support the view that utility measurement is sensitive to the method chosen to elicit patient well being.

Entities:  

Mesh:

Year:  1994        PMID: 8182636

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

2.  Vision and quality-of-life.

Authors:  G C Brown
Journal:  Trans Am Ophthalmol Soc       Date:  1999

3.  How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

Authors:  Annelies Boonen; Désirée van der Heijde; Robert Landewé; Astrid van Tubergen; Herman Mielants; Maxime Dougados; Sjef van der Linden
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

4.  The effect of assessment method and respondent population on utilities elicited for Gaucher disease.

Authors:  A E Clarke; M K Goldstein; D Michelson; A M Garber; L A Lenert
Journal:  Qual Life Res       Date:  1997-03       Impact factor: 4.147

5.  Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population.

Authors:  Seon-Ha Kim; Sang-Il Lee; Min-Woo Jo
Journal:  Qual Life Res       Date:  2017-08-11       Impact factor: 4.147

6.  Predicting patients' utilities from quality of life items: an improved scoring system for the UBQ-H.

Authors:  A J Martin; P P Glasziou; R J Simes; T Lumley
Journal:  Qual Life Res       Date:  1998-12       Impact factor: 4.147

7.  Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis.

Authors:  Chili Lati; Lori C Guthrie; Michael M Ward
Journal:  J Rheumatol       Date:  2010-03-01       Impact factor: 4.666

8.  Standards of Comparison and Discordance in Rheumatoid Arthritis Global Assessments Between Patients and Clinicians.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08       Impact factor: 4.794

9.  Variables related to utility in patients with ankylosing spondylitis.

Authors:  Rafael Ariza-Ariza; Blanca Hernández-Cruz; Gloria López-Antequera; Federico Navarro-Sarabia
Journal:  Clin Rheumatol       Date:  2008-09-30       Impact factor: 2.980

10.  Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.

Authors:  A Boonen; R van den Heuvel; A van Tubergen; M Goossens; J L Severens; D van der Heijde; S van der Linden
Journal:  Ann Rheum Dis       Date:  2004-07-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.